Free Trial

IntelGenx Technologies Q1 2023 Earnings Report

IntelGenx Technologies logo
$0.17 0.00 (0.00%)
As of 04/4/2025

IntelGenx Technologies EPS Results

Actual EPS
-$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

IntelGenx Technologies Revenue Results

Actual Revenue
$0.16 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

IntelGenx Technologies Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Remove Ads

IntelGenx Technologies Earnings Headlines

Gold Hits $3,000… Here’s How You Can Get More for Under $20
With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively stockpiling gold at any price, the market is showing no signs of slowing down. In fact, gold has recently reached new all-time highs, driven by expectations of interest rate cuts and increasing safe-haven demand. This trend has led to a significant boost in gold mining stocks and gold-focused investment funds. But here's the exciting part: I've found a way to get exposure to MORE than an ounce of gold for under $20.
See More IntelGenx Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IntelGenx Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IntelGenx Technologies and other key companies, straight to your email.

About IntelGenx Technologies

IntelGenx Technologies (OTCMKTS:IGXT), a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

View IntelGenx Technologies Profile

More Earnings Resources from MarketBeat